Clinical Trial

Large Language Model-Based Emotional Management for Breast Cancer Patients

Study acronym: EMBRACE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study (study type: randomized controlled trial) aims to evaluate whether a large language model-based precision emotional management intervention can improve health-related quality of life among patients with primary breast cancer. The study will enroll adult women (≥18 years old) with pathologically confirmed primary breast cancer who own a smartphone, regularly use social media platforms, and have an expected survival of at least 6 months. The primary questions this study seeks to answer are: 1. Does the intervention improve health-related quality of life (EORTC QLQ-C30 summary score) at 6 months post-intervention? 2. Does the intervention reduce anxiety, depression, cancer-related symptom burden, and unplanned hospitalizations in this population? With a control group in place, researchers will compare changes in health-related quality of life, anxiety, depression, and cancer-related symptom burden between the intervention group (receiving digital precision emotional management plus usual care) and the control group (receiving usual care only) to determine whether the intervention leads to significant improvements in these outcomes. Participants will be required to: 1. Complete baseline and follow-up assessments of health-related quality of life, anxiety, depression, and cancer-related symptoms at 1, 3, and 6 months post-randomization. 2. For those in the intervention group, use the digital precision emotional management system autonomously for 6 months, including submitting self-reported emotional diaries and completing biweekly skill translation assessments. 3. For all participants, report any adverse events and unplanned hospitalizations during the study period.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-07-29
notable Primary completion pushed: 2026-10-01 -> 2026-11-30 2026-07-29
minor Completion pushed: 2026-11-01 -> 2026-12-20 2026-07-29
Trial Details
NCT Number NCT07452055
Lead Sponsor Nanfang Hospital, Southern Medical University
Conditions Primary Breast Cancer
Enrollment 440 participants
Start Date 2026-03-24
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-12